Maria E Rodriguez-Ruiz

10PUBLICATIONS
102CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsInstruments and techniques
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 04, 2026
Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy.

|Jan 16, 2026
Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.

Miguel F Sanmamed, Carlos E de Andrea, David Ruiz-Guillamon

|Feb 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors.

Valentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz

|Feb 11, 2025
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models.

Eneko Garate-Soraluze, Irantzu Serrano-Mendioroz, Leticia Fernández-Rubio

|Aug 30, 2024
NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma.

Olaya de Dios, M Angeles Ramírez-González, Irene Gómez-Soria

|Apr 17, 2024
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors.

Neeltje Steeghs, Carlos Gomez-Roca, Kristoffer S Rohrberg

Pageof 2

Frequent Collaborators

6 joint publications

Ignacio Melero

3 joint publications

Alvaro Teijeira

3 joint publications

Eneko Garate-Soraluze

2 joint publications

Gabriel Gomis